Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
2(18%)
Results Posted
25%(1 trials)
Terminated
2(18%)

Phase Distribution

Ph phase_4
1
9%
Ph phase_3
6
55%
Ph phase_1
4
36%

Phase Distribution

4

Early Stage

0

Mid Stage

7

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
4(36.4%)
Phase 3Large-scale testing
6(54.5%)
Phase 4Post-market surveillance
1(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

2

trials recruiting

Total Trials

11

all time

Status Distribution
Active(2)
Completed(4)
Terminated(2)
Other(3)

Detailed Status

Completed4
unknown3
Terminated2
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
2
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (36.4%)
Phase 36 (54.5%)
Phase 41 (9.1%)

Trials by Status

recruiting19%
active_not_recruiting19%
unknown327%
terminated218%
completed436%

Recent Activity

2 active trials
Showing 5 of 11
recruitingphase_1

Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

NCT05181735
active_not_recruitingphase_3

A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS

NCT03223961
completedphase_3

Study to Compare the Safety and Efficacy of UB-851 and Eprex®

NCT02708914
completedphase_3

Biosimilar Erythropoietin in Anaemia Treatment (Maintenance Phase Study)

NCT02947438
completedphase_1

Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects.

NCT03572647
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT05181735Phase 1

Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

Recruiting
NCT03223961Phase 3

A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS

Active Not Recruiting
NCT02708914Phase 3

Study to Compare the Safety and Efficacy of UB-851 and Eprex®

Completed
NCT02947438Phase 3

Biosimilar Erythropoietin in Anaemia Treatment (Maintenance Phase Study)

Completed
NCT03572647Phase 1

Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects.

Completed
NCT02522975Phase 4

Biosimilar Erythropoietin in Anaemia Treatment (Correction Phase Study)

Terminated
NCT03408639Phase 3

Comparing Efficacy and Safety of CinnaGen Beta Erythropoietin (CinnaPoietin®) Versus Eprex® on the Treatment of Anemia in ESRD Hemodialysis Patients

Completed
NCT03521713Phase 3

To Evaluate the Efficacy, Safety, and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex)

Unknown
NCT01695759Phase 3

Clinical Efficacy of Two Erythropoietin Drug in Participants With Secondary Anemia to Chronic Kidney Disease.

Terminated
NCT03276910Phase 1

Evaluation of Erythroferrone as a New Biomarker of Erythropoesis Stimulating Agents

Unknown
NCT02580006Phase 1

To Investigate the Pharmacokinetics of EPORON® and EPREX® After Subcutaneous Administration in Healthy Male Volunteers

Unknown

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11